Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Clinical Advances in Hematology & Oncology : H&O|March 19, 2021
Antibody treatment in multiple myelomaKathryn T Maples, Catherine Johnson, Sagar LonialClinical Advances in Hematology & Oncology : H&O|May 5, 2023
Novel approaches to the treatment of multiple myelomaKathryn T Maples, Sara A Scott, Sagar LonialExpert Review of Anticancer Therapy|September 24, 2020
Current developments in the combination therapy of relapsed/refractory multiple myelomaKathryn T Maples, Nisha S Joseph, R Donald HarveyThe Annals of Pharmacotherapy|February 27, 2016
Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk NeuroblastomaCady Ploessl, Alice Pan, Kathryn T Maples, et al.The Annals of Pharmacotherapy|December 29, 2021
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational ConsiderationsJustin R Arnall, Kathryn T Maples, R Donald Harvey, et al.Leukemia & Lymphoma|April 5, 2018
Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignanciesKathryn T Maples, Roy T Sabo, John M McCarty, et al.Pharmacotherapy|August 19, 2018
Current and Investigational Agents Targeting the Phosphoinositide 3-Kinase PathwayLaura A Tang, Brianne N Dixon, Kathryn T Maples, et al.The Annals of Pharmacotherapy|February 22, 2020
Management of Mantle Cell Lymphoma in the Era of Novel Oral AgentsMichael J Buege, Anita Kumar, Brianne N Dixon, et al.Pharmacotherapy|February 5, 2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantAkhilesh Sivakumar, Evan B Bryson, Kevin H Hall, et al.JCO Oncology Practice|July 7, 2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib InductionLaura F Sun, Kathryn T Maples, Kevin H Hall, et al.Pageof 2